How can a scout write a concise deal memo about a healthcare software startup?

A scout memo should make the opportunity and the open questions understandable quickly. Describe the customer, problem, workflow, evidence, team, round context, and fit with the fund. Distinguish a source's claim from the scout's own interpretation.

Start with the decision

Use a short claim-evidence-question structure. Link public or permissioned supporting materials and state their dates. Include a reason the company might not fit rather than treating the memo as a sales document.

The illustrative scenario

This is an educational workbook. The company or fund and all numerical inputs below are fictional. They are not ADIN results, customer claims, market benchmarks, or a forecast.

The fictional team is piloting an administrative scheduling product with a provider group. Staff use it in a narrow workflow, while procurement and data review determine whether a broader rollout is possible.

A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval.

Turn the scenario into an evidence decision

Consider a review of a healthcare software startup in which a confident explanation arrives before the supporting records. Start with the first question in the table. Write down what an answer would change: the next interview, the experiment's scope, a request for specialist review, or a decision to wait. A question without a consequence can produce a longer document while adding little understanding.

Next, inspect the record named in the table and record its date, owner, permission boundary, and limitations. Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet. If the record contradicts the explanation, preserve both accounts and ask which definition, period, or workflow differs. Do not silently select the version that makes the opportunity look strongest.

Finish with a conditional statement: if the specified evidence supports the claim under these conditions, take the named next step; otherwise investigate the unresolved question. The memo is useful when it helps the investment team choose its next inquiry. Length and confidence cannot substitute for relevant evidence, and the fund retains the authority defined by the program. This worked exercise is about the decision process. It does not assert that a fictional company has met a real diligence standard or that a template can authorize an investment.

Use this worksheet

Answer the questions with a source, date, owner, and next action. Mark an unknown as unknown. Use public or permissioned information and involve a qualified specialist when a question requires expertise beyond the team’s competence.

1. Who is the customer?
2. What evidence is available?
3. Why does this fund fit?
4. What is the biggest unresolved question?
5. What would change the scout's view?

Questions specific to this scenario

• Which workflow is actually in scope?
• Who approves data access?
• What specialist review is needed?

Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet.

A concrete next test

Ask the authorized workflow owner to map a narrow administrative use case without disclosing patient information. Identify the data-access and procurement approvals needed for the next step. Keep operational adoption evidence separate from claims about clinical benefit or regulatory status.

Interpret the result

The memo is useful when it helps the investment team choose its next inquiry. Length and confidence cannot substitute for relevant evidence, and the fund retains the authority defined by the program.

Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence.

Sources and method

These primary resources provide background for the concepts. The fictional scenario, calculations, and worksheet are ADIN educational examples; the sources do not report or validate those invented results. Reviewed October 11, 2026.

• Hustle Fund: Venture Capital Scout Programs
• Investor.gov: Private Equity Funds